Open AccessNeoadjuvant chemotherapy in woman with early or locally advanced cervical cancer
Author(s) -
Marcela de la Torre
Publication year - 2018
Publication title -
reports of practical oncology and radiotherapy
Language(s) - English
Resource type - Journals
eISSN - 2083-4640
pISSN - 1507-1367
DOI - 10.1016/j.rpor.2018.09.005
Subject(s) - medicine , cervical cancer , clinical trial , context (archaeology) , chemotherapy , radiation therapy , oncology , concomitant , clinical practice , cancer , randomized controlled trial , surgery , physical therapy , paleontology , biology
Cervical cancer is a major global health problem for women. Despite the screening and vaccines available today, it continues to be the fourth most common cancer in women worldwide with 85% of cases occurring in developing countries. Standard treatments for early or locally advanced cervical cancer are surgery (S) or concomitant chemo-radiotherapy (CT-RT). Neoadjuvant chemotherapy (NACT) prior to surgery or radiotherapy has been proposed and tested in clinical trials and has been included in clinical practice in some countries.In order to determine the true role of NACT either prior to S or RT in terms of achieving benefits in OS or DFS, randomized clinical trials and meta-analyses published from its beginnings to the present have been searched and analyzed in this study.The analysis of published clinical trials shows that NACT followed by S and NACT followed by RT have failed to demonstrate benefits in OS or DFS. Clinical trials comparing NACT followed by S versus exclusive RT have also been analyzed, where NACT followed by S could not show benefits for RT either.